

Buy

View: Execution momentum to continue; maintain Buy

- HGINFRA reported results above estimates on all fronts.
- HGINFRA reported 206.0%/ 202.3%/ 489.3% YoY growth in revenue/ EBITDA/ PAT to Rs9.1 bn/ Rs1.5 bn/ Rs889 mn in Q1FY22.
- We increase our revenue estimates by 4.0%/ 6.7% and broadly maintain EBITDA margin estimates for FY22E/ FY23E factoring Q1FY22 results. Accordingly, we increase our PAT estimated by 8.0%/ 10.9% for FY22E/ FY23E. HG has received appointed date for all its projects (except Rs18.4 bn 3 HAM projects & 1 EPC project of Rs12.4 bn) and entire execution benefit will be realized in FY22E. We expect 29.9%/ 18.1% revenue growth for FY22E/ FY23E.
- We expect revenue/ Adj. PAT CAGR of 23.8%/ 22.7% over FY21-23E. Though the stock has increased ~95% since our Q4FY21 result on 14 May'21, it still looks reasonably attractive at 14.0x/ 11.7x FY22E/ FY23E EPS, hence we maintain BUY with SOTP of Rs695 (12x FY23E EPS) and 1x FY23E P/B for HAM equity investments. We factor Rs2.4 bn/ Rs2.5 bn equity investment in HAM for FY22E/ FY23E).
- Key Risk - Strong order inflows in FY22E for better execution in FY23E**

Robust return ratios coupled with comfortable working capital

We expect NWC (excluding cash) days to remain at a comfortable level of 103/ 103 days in FY22E/ FY23E vs. 115/ 91 in FY20/ FY21. We expect 0.21x/ 0.2x Net D:E for FY22E/ FY23E and healthy return ratios (average RoE/ RoCE of 22.4%/ 22.3% over FY21-23E), led by strong PAT growth, comfortable NWC days, healthy balance sheet, and healthy fixed asset turnover.

Order book at 2.4x TTM revenue

HGINFRA won orders worth Rs21.8 bn/ Rs12.4 bn during FY21/ YTD FY22. The current order book of Rs73.9 bn provides revenue visibility for 2.4x TTM revenue. We maintain our order inflow estimates of Rs50 bn each for FY22E/ FY23E.

Q1FY22 Result (Rs Mn)

Particulars	Q1FY22	Q1FY21	YoY (%)	Q4FY21	QoQ (%)
Revenue	9,117	2,979	206.0	10,278	(11.3)
Total Expense	7,632	2,488	206.7	8,613	(11.4)
EBITDA	1,485	491	202.3	1,665	(10.8)
Depreciation	203	195	4.3	226	(10.1)
EBIT	1,282	297	332.3	1,439	(10.9)
Other Income	34	27	27.8	77	(56.2)
Interest	119	122	(2.3)	192	(38.2)
EBT	1,197	201	494.6	1,324	(9.6)
Tax	308	50	510.5	348	(11.3)
RPAT	889	151	489.3	977	(9.0)
APAT	889	151	489.3	977	(9.0)
			(bps)		(bps)
Gross Margin (%)	20.6	25.4	(474)	20.1	57
EBITDA Margin (%)	16.3	16.5	(20)	16.2	9
NPM (%)	9.8	5.1	469	9.5	25
Tax Rate (%)	25.7	25.1	67	26.2	(51)
EBIT Margin (%)	14.1	10.0	411	14.0	6

CMP	Rs 572
Target / Upside	Rs 695 / 21%
NIFTY	16,295

Scrip Details

Equity / FV	Rs 652mn / Rs 10		
Market Cap	Rs 37bn		
	USD 503mn		
52-week High/Low	Rs 630/ 174		
Avg. Volume (no)	5,60,392		
Bloom Code	HGINFRA IN		
Price Performance	1M	3M	12M
Absolute (%)	24	103	219
Rel to NIFTY (%)	21	92	175

Shareholding Pattern

	Dec'20	Mar'21	Jun'21
Promoters	74.0	74.5	74.5
MF/Banks/FIs	19.1	18.2	16.5
FIIIs	0.4	0.1	0.5
Public / Others	6.4	7.2	8.5

Valuation (x)

	FY21A	FY22E	FY23E
P/E	17.7	14.0	11.7
EV/EBITDA	9.2	7.9	6.7
ROE (%)	22.8	22.9	21.9
RoACE (%)	21.7	22.8	21.9

Estimates (Rs mn)

	FY21A	FY22E	FY23E
Revenue	25,275	32,836	38,766
EBITDA	4,107	5,088	6,008
PAT	2,110	2,667	3,178
EPS (Rs.)	32.4	40.9	48.8

VP Research: Shravan Shah
Tel: +91 22 40969749
E-mail: shravans@dolatcapital.com

Associate: Maulik Shah
Tel: +91 22 40969775
E-mail: mauliks@dolatcapital.com

Associate: Parth Bhavsar
Tel: +91 22 40969775
E-mail: parthb@dolatcapital.com

Exhibit 1: Actual vs. DART estimates (Rs mn)

Particulars	Actual	DART Est	% Variance	Comments
Revenue (Rs mn)	9,117	8,528	6.9	Better execution vs. estimated
EBITDA (Rs mn)	1,485	1,313	13.2	-
EBITDA%	16.3	15.4	90	Led by lower employee and other expenses
PAT (Rs mn)	889	676	31.6	Better operating performance vs. estimated

Source: Company, DART

Exhibit 2: Change in estimates – Upgrade FY22E/ FY23E estimates

(Rs mn)	FY22E			FY23E		
	New	Old	% change	New	Old	%change
Net revenues	32,836	31,585	4.0	38,766	36,337	6.7
EBIDTA	5,088	4,857	4.8	6,008	5,589	7.5
EBIDTA margin (%)	15.50	15.4	12 bps	15.50	15.38	12 bps
Adj. Net Profit	2,667	2,470	8.0	3,178	2,867	10.9
EPS (Rs)	40.9	37.9	8.0	48.8	44.0	10.9

Source: DART, Company

Key earnings takeaways

- Opportunities – Jal Jeevan mission has good opportunities, Rajasthan itself has Rs80 bn worth of projects to be awarded in FY22E. Railways has High speed rail opportunities. Expect more awards in FY22E vs. awards in FY21. NHAI is likely to award 65-70% HAM projects in FY22E.
- Pre-qualification of Railways is Rs10 bn and for Water on a standalone basis is Rs500 mn however, in JV with one south player, HG is qualified to bid for projects worth Rs1.5-2 bn.
- HG has bid for 4 Railway projects from IRCON worth Rs13 bn, 6 NHAI EPC projects worth Rs45 bn and 5-6 NHAI HAM projects worth Rs60 bn. The bids are not open yet and are spread across Maharashtra, Chhattisgarh and North regions.
- HG had a bid to win success ratio of 4%/ 10-12% in HAM projects in FY21/ FY20. On the EPC side, success ratio was 10% in FY20. Total opportunity size on HAM/ EPC/ BOT Toll front is Rs1.25 tn/ Rs500 bn/ Rs150-200 bn.
- HG expects to win additional order inflow of Rs50-60 bn in FY22E of which Rs5-8 bn can be from water and railways segment. It expects 10% contribution to OB from these segments and will further increase to 25% by FY24E/25E. HG doesn't rule out sub-contracting work.
- HG is confident of over achieving its revenue growth guidance of 25-30% for FY22E. Out of total orderbook of Rs73.9 bn, only Rs43 bn worth of orders are under execution and HG is confident of executing Rs23 bn in 9 months of FY22E. HG will not compromise on margins.
- Physical progress - Gurgaon Sohna 87%, Hapur Moradabad 60%, Delhi Vadodara Pkg-4 75%, Narnaul Bypass 75%, Rewari Ateli 72%, Delhi Vadodara Pkg 8 30%, Delhi Vadodara Pkg 9 25% done, Rewari 19% done, Mancheria 30% done and Rajasthan projects 85-95% done and has applied for PCOD. Expect 90-95% Hapur project to get completed by Mar'22.
- Expect Raipur HAM project to get AD by Jan-Feb'22 (60% land available) and Khammam HAM AD by April-May'22. Karala EPC has more than 90% land available and can start execution by Dec'21.

- Equity investment in HAM – Expect total equity investment of Rs4.5 bn for HAM projects of which Rs1.5 bn in FY22E (Rs900 mn for old HAM and Rs600 mn for new HAM), Rs2 bn in FY23E and Rs1 bn in FY24E.
- On HAM monetization, some investors are keen and one Invit is also interested. This may take 6-8 months to complete and expect a positive outlook.
- Rajasthan projects funded by WB – Debtors improving and pending is Rs370 mn (Rs90 mn received in Jul'21) which is expected to clear in Q3FY22E.
- Debtors from major projects – Total debtors increased by Rs1.3 bn to Rs8.36 bn. Adani/ IRB debtors stands at Rs490 mn/ Rs1.72bn. Inventory/ Payables stands at Rs1.86 bn/ Rs5 bn.
- Gross Debt stands at Rs3.1 bn (Jun'21) vs. Rs2.9 bn (Mar'21) vs. Rs3.8 bn (Jun'20). Cash stands at Rs1.5 bn.
- Capex guidance of Rs700 mn for FY22E (Rs290 mn already spent in Q1FY22E).
- Retention money/ Mobilization advance/ Unbilled revenue stood at Rs2.4 bn/ Rs2.67 bn/ Rs2.46 bn.
- No need to raising Rs3 bn via QIP or any other means as of now. As NHAI is planning to award more projects under HAM, HG wants to be ready to bid and win more orders.

Exhibit 3: Income statement (Standalone)


Particulars (Rs mn)	Q1FY22	Q1FY21	YoY (%)	Q4FY21	QoQ (%)	FY21	FY20	YoY (%)
Revenue	10,278	6,229	65.0	7,343	40.0	25,275	21,961	15.1
Material consumed	4,628	2,381	94.4	3,376	37.1	11,857	8,926	32.8
Subcontract work	3,589	2,426	48.0	2,396	49.8	7,952	8,137	(2.3)
Employees cost	296	291	1.9	315	(5.9)	1,093	1,114	(1.9)
Other expenditure	100	118	(14.8)	76	32.7	267	360	(25.8)
Total expenditure	8,613	5,215	65.2	6,162	39.8	21,168	18,538	14.2
EBITDA	1,665	1,014	64.2	1,181	41.0	4,107	3,424	19.9
Depreciation	226	208	8.4	216	4.7	844	756	11.6
Operating profit	1,439	806	78.6	966	49.0	3,262	2,668	22.3
Other income	77	38	104.4	34	125.1	154	137	13.0
EBIT	1,517	844	79.8	1,000	51.7	3,417	2,804	21.8
Interest	192	159	21.3	144	33.9	596	524	13.7
EBT	1,324	685	93.3	856	54.6	2,821	2,281	23.7
Tax	348	172	101.5	201	73.1	712	623	14.2
Net income	977	513	90.6	655	49.0	2,110	1,657	27.3
EPS (Rs)	15.0	7.9	90.6	10.1	49.0	32.4	25.4	27.3
			bps		bps			bps
EBIDTA Margin (Excl. O.I.)	16.3	16.5	(20)	16.2	9	16.2	15.6	66
EBIDTA Margin (Incl. O.I.)	16.7	17.4	(72)	17.0	(29)	16.9	16.2	65
NPM (%)	9.7	5.0	470	9.4	29	8.3	7.5	80
Tax/PBT (%)	25.7	25.1	67	26.2	(51)	25.2	27.3	(211)
Material cons/Revenue (%)	79.4	74.6	474	79.9	(57)	78.4	77.7	67

Source: DART, Company


Exhibit 4: SOTP Valuation

Component	Valuation Method	Rs/sh	%
Standalone cons business	12x FY23E EPS	585.2	84.2
HAM Projects	1x FY23E P/B	109.7	15.8
Total		694.9	100.0
CMP		572.4	
Potential upside (%)		21.4	


Source: DART, Company

Exhibit 5: Rs61.4 bn geographical break up



Source: Company, DART

Exhibit 6: Orderbook trend



Source: Company, DART

Exhibit 7: 23.8% revenue CAGR over FY21-23E



Source: Company, DART

Exhibit 8: EBITDA margins trend


Source: Company, DART

Exhibit 9: Stable leverage


Source: Company, DART

Exhibit 10: Healthy return ratios


Source: Company, DART

Profit and Loss Account

(Rs Mn)	FY20A	FY21A	FY22E	FY23E
Revenue	21,961	25,275	32,836	38,766
Total Expense	18,542	21,168	27,747	32,758
COGS	17,064	19,808	26,081	30,765
Employees Cost	1,114	1,093	1,278	1,470
Other expenses	365	267	388	523
EBIDTA	3,419	4,107	5,088	6,008
Depreciation	756	844	956	1,096
EBIT	2,663	3,262	4,133	4,912
Interest	524	596	670	750
Other Income	141	154	123	111
Exc. / E.O. items	0	0	0	0
EBT	2,281	2,821	3,586	4,274
Tax	623	712	919	1,095
RPAT	1,657	2,110	2,667	3,178
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
APAT	1,657	2,110	2,667	3,178

Balance Sheet

(Rs Mn)	FY20A	FY21A	FY22E	FY23E
Sources of Funds				
Equity Capital	652	652	652	652
Minority Interest	0	0	0	0
Reserves & Surplus	7,564	9,670	12,285	15,411
Net Worth	8,216	10,322	12,937	16,063
Total Debt	3,675	2,890	3,267	3,867
Net Deferred Tax Liability	(87)	(95)	(95)	(95)
Total Capital Employed	11,804	13,117	16,109	19,835

Applications of Funds

Net Block	4,824	4,831	4,867	5,022
CWIP	111	18	0	0
Investments	908	2,612	5,003	7,497
Current Assets, Loans & Advances	14,754	14,250	16,482	19,407
Inventories	1,055	1,680	2,220	2,621
Receivables	8,111	6,575	9,071	10,701
Cash and Bank Balances	1,144	2,584	598	677
Loans and Advances	74	50	50	50
Other Current Assets	4,369	3,361	4,545	5,358
Less: Current Liabilities & Provisions	8,794	8,595	10,244	12,091
Payables	8,314	8,220	9,795	11,564
Other Current Liabilities	480	374	449	528
<i>sub total</i>				
Net Current Assets	5,960	5,656	6,238	7,316
Total Assets	11,804	13,117	16,109	19,835

E – Estimates

Important Ratios

Particulars	FY20A	FY21A	FY22E	FY23E
(A) Margins (%)				
Gross Profit Margin	22.3	21.6	20.6	20.6
EBIDTA Margin	15.6	16.2	15.5	15.5
EBIT Margin	12.1	12.9	12.6	12.7
Tax rate	27.3	25.2	25.6	25.6
Net Profit Margin	7.5	8.3	8.1	8.2
(B) As Percentage of Net Sales (%)				
COGS	77.7	78.4	79.4	79.4
Employee	5.1	4.3	3.9	3.8
Other	1.7	1.1	1.2	1.4
(C) Measure of Financial Status				
Gross Debt / Equity	0.4	0.3	0.3	0.2
Interest Coverage	5.1	5.5	6.2	6.5
Inventory days	18	24	25	25
Debtors days	135	95	101	101
Average Cost of Debt	14.0	18.1	21.8	21.0
Payable days	138	119	109	109
Working Capital days	99	82	69	69
FA T/O	4.6	5.2	6.7	7.7
(D) Measures of Investment				
AEPS (Rs)	25.4	32.4	40.9	48.8
CEPS (Rs)	37.0	45.3	55.6	65.6
DPS (Rs)	0.6	0.0	0.8	0.8
Dividend Payout (%)	2.4	0.0	2.0	1.6
BVPS (Rs)	126.1	158.4	198.5	246.5
RoANW (%)	22.4	22.8	22.9	21.9
RoACE (%)	19.7	21.7	22.8	21.9
RoAIC (%)	21.8	25.5	25.6	22.7
(E) Valuation Ratios				
CMP (Rs)	572	572	572	572
P/E	22.5	17.7	14.0	11.7
Mcap (Rs Mn)	37,304	37,304	37,304	37,304
MCap/ Sales	1.7	1.5	1.1	1.0
EV	39,835	37,610	39,973	40,493
EV/Sales	1.8	1.5	1.2	1.0
EV/EBITDA	11.6	9.2	7.9	6.7
P/BV	4.5	3.6	2.9	2.3
Dividend Yield (%)	0.1	0.0	0.1	0.1
(F) Growth Rate (%)				
Revenue	9.3	15.1	29.9	18.1
EBITDA	12.8	20.1	23.9	18.1
EBIT	16.9	22.5	26.7	18.9
PBT	19.9	23.7	27.1	19.2
APAT	34.1	27.3	26.4	19.2
EPS	34.1	27.3	26.4	19.2

Cash Flow

(Rs Mn)	FY20A	FY21A	FY22E	FY23E
CFO	2,550	5,273	1,626	3,915
CFI	(1,688)	(2,421)	(3,267)	(3,633)
CFE	(720)	(1,412)	(345)	(202)
FCFF	1,618	4,408	626	2,665
Opening Cash	1,002	1,144	2,584	598
Closing Cash	1,144	2,584	598	677


E – Estimates

DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
Aug-20	Buy	330	192
Sep-20	Buy	330	200
Nov-20	Buy	375	186
Jan-21	Buy	410	217
Feb-21	Buy	410	313
May-21	Buy	506	293

*Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747
--------------------	--------------------------	--------------------------------	------------------------

Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745
--------------------------	-------------------------	------------------------------	------------------------

CONTACT DETAILS

Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Jubbin Shah	VP - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772
Anjana Jhaveri	VP - FII Sales	anjanaj@dolatcapital.com	+9122 4096 9758
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740
Equity Trading	Designation	E-mail	
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715
Dinesh Mehta	Co - Head Asia Derivatives	dinesh.mehta@dolatcapital.com	+9122 4096 9765
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705

Dolat Capital Market Private Limited.

Sunshine Tower, 28th Floor, Senapati Bapat Marg, Dadar (West), Mumbai 400013

Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: "This Report is considered independent third-party research and was prepared by Dolat Capital Market Private Limited, with headquarters in India. The distribution of this Research is provided pursuant to the exemption under Rule 15a-6(a) (2) and is only intended for an audience of Major U.S. Institutional Investors (MUSIIs) as defined by Rule 15a-6(b)(4). This research is not a product of StoneX Financial Inc. Dolat Capital Market Private Limited has sole control over the contents of this research report. StoneX Financial Inc. does not exercise any control over the contents of, or the views expressed in, any research reports prepared by Dolat Capital Market Private Limited and under Rule 15a-6(a) (3), any U.S. recipient of this research report wishing to affect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through StoneX Financial Inc. Please contact Paul Karrlsson-Willis at +1 (407) 741-5310 or email Paul.Karrlsson-Willis@stonex.com and/or Igor Chernomorskiy at +1 (212)379-5463 or email Igor.Chernomorskiy@stonex.com. Under no circumstances should any U.S. recipient of this research report effect any transaction to buy or sell securities or related financial instruments through the Dolat Capital Market Private Limited."



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INZ000274132, NSE - INZ000274132, Research: INH000000685

Registered office: Unit no PO6-02A - PO6-02D, Tower A, WTC, Block 51, Zone-5, Road 5E, Gift City, Gandhinagar, Gujarat – 382355

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com
